Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome.
The induction of genes of host cells stimulated by microbial products such as endotoxin and the tolerance of cells to endotoxin excitation play critical roles in the pathogenesis of microbial-induced acute disseminated inflammation with multiorgan failure (the sepsis syndrome). One gene that is induced in phagocytic cells by endotoxin and that appears to play an essential role in the pathogenesis of the sepsis syndrome is IL-1 beta. We report here that blood neutrophils (PMN) of patients with the sepsis syndrome (sepsis PMN) are consistently tolerant to endotoxin-induced expression of the IL-1 beta gene, as determined by decreased synthesis of the IL-1 beta protein and reductions in IL-1 beta mRNA. This down-regulation of the IL-1 beta gene in sepsis PMN occurs concomitant with an upregulation in the constitutive expression of the type 2 IL-1 receptor (IL-1R2). These phenotypic changes do not persist in PMN of patients recovering from the sepsis syndrome. Tolerance has stimulus and response specificity since sepsis PMN tolerant to endotoxin can respond normally to Staphylococcus aureus stimulation of IL-1 beta production and they normally secrete elastase. Uninfected patients with severe trauma or shock from causes are not tolerant to endotoxin and tolerance is not limited to patients infected with Gram-negative bacteria. The mechanism responsible for tolerance involves pretranslational events and is not due to loss of the CD14 surface protein, a receptor required for endotoxin induction of IL-1 beta in PMN. The physiological significance of the tolerance to endotoxin and increased expression of IL-1R2 on sepsis PMN is unknown, but may represent an attempt by the host to protect itself from the deleterious effects of disseminated inflammation.
McCall
C E
CE
Department of Medicine, Wake Forest University Medical Center, Winston-Salem, North Carolina 27157.
Grosso-Wilmoth
L M
LM
LaRue
K
K
Guzman
R N
RN
Cousart
S L
SL
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D015152:Blotting, Northern; D002478:Cells, Cultured; D004731:Endotoxins / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis / Q000235:genetics*; D019272:Leukocyte Elastase; D018950:Lipopolysaccharide Receptors; D009102:Multiple Organ Failure / Q000097:blood* / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D010196:Pancreatic Elastase / Q000032:analysis; D011061:Poly A / Q000235:genetics / Q000302:isolation & purification; D012313:RNA / Q000235:genetics / Q000302:isolation & purification; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics; D017472:Receptors, Interleukin-1 / Q000378:metabolism; D012016:Reference Values; D018805:Sepsis / Q000097:blood* / Q000276:immunology; D013577:Syndrome; D014947:Wounds and Injuries / Q000150:complications
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D004731:Endotoxins; D007375:Interleukin-1; D018950:Lipopolysaccharide Receptors; D012333:RNA, Messenger; D017472:Receptors, Interleukin-1; D011061:Poly A; D012313:RNA; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase